Page 150 - 南京医科大学自然版

第46卷第9期
·1420 · 南 京 医 科 大 学 学 报 2026年9月

tance［J］. J Med Chem，2025，68（3）：3886-3899 1）：127657
［51］WANG Y Z，LIU J X，ZHANG Y H，et al. Rational design ［63］ZLINSKA V，FEKETOVA Z，CZYREK A，et al. Specific
and identification of ISM7594 as a tissue⁃agnostic FGFR2/ inhibition of fibroblast growth factor receptor 1 signaling
3 inhibitor［J］. J Med Chem，2025，68（13）：13887-13906 by a DNA aptamer［J］. Mol Ther Nucleic Acids，2025，36
［52］HUDKINS R L，ALLEN E，BALCER A，et al. Discovery of （1）：102405
TYRA ⁃ 300：first oral selective FGFR3 inhibitor for the ［64］HERNÁNDEZ⁃BOLUDA J C，PEREIRA A，ZINGER N，
treatment of urothelial cancers and achondroplasia［J］. J et al. Allogeneic hematopoietic cell transplantation in pa⁃
Med Chem，2024，67（18）16737-16756 tients with myeloid/lymphoid neoplasm with FGFR1⁃rear⁃
［53］STARRETT J H，ALLEN E L，NEAL M，et al. Dabogratinib rangement：a study of the Chronic Malignancies Working
（TYRA⁃300），an FGFR3 isoform⁃selective inhibitor：pre⁃ Party of EBMT［J］. Bone Marrow Transplant，2022，57
clinical and initial clinical evidence of antitumor activity［J］. （3）：416-422
Mol Cancer Ther，2026，25（3）：408-415 ［65］LAMARCA A，OSTIOS L，MCNAMARA M G，et al. Resis⁃
［54］JAVLE M，FOUNTZILAS C，LIAO C Y，et al. Tinengo⁃ tance mechanism to fibroblast growth factor receptor（FG⁃
tinib for adults with advanced or metastatic cholangiocar⁃ FR）inhibitors in cholangiocarcinoma［J］. Cancer Treat
cinoma：a multicentre，open⁃label，phase 2 trial［J］. Lan⁃ Rev，2023，121：102627
cet Gastroenterol Hepatol，2026，11（2）：137-149 ［66］GOYAL L，DITORO D，FACCHINETTI F，et al. A model
［55］UEMOTO Y，LIN C A，WANG B N，et al. Selective degra⁃ for decoding resistance in precision oncology：acquired re⁃
dation of FGFR1/2 overcomes antiestrogen resistance in sistance to FGFR inhibitors in cholangiocarcinoma［J］.
ER+ breast cancer with FGFR1/2 alterations［J］. Cancer Ann Oncol，2025，36（4）：426-443
Lett，2025，619：217668 ［67］BAYLE A，BELCAID L，ALDEA M，et al. Clinical utility
［56］BROWN L M，EKERT P G，FLEUREN E D G. Biological of circulating tumor DNA sequencing with a large panel：a
and clinical implications of FGFR aberrations in paediat⁃ National Center for Precision Medicine（PRISM）study［J］.
ric and young adult cancers［J］. Oncogene，2023，42 Ann Oncol，2023，34（4）：389-396
（23）：1875-1888 ［68］FACCHINETTI F，LORIOT Y，BRAYÉ F，et al. Under⁃
［57］HU Z L，ZHANG Q S，LI Z L，et al. Design，synthesis and standing and overcoming resistance to selective FGFR in⁃
antitumor activity of a novel FGFR2⁃selective degrader to hibitors across FGFR2⁃driven malignancies［J］. Clin Can⁃
overcome resistance of the FGFR2V564F gatekeeper mu⁃ cer Res，2024，30（21）：4943-4956
tation based on a pan ⁃ FGFR inhibitor［J］. Eur J Med ［69］WU Q B，ELLIS H，SIRAVEGNA G，et al. Landscape of
Chem，2024，275：116612 clinical resistance mechanisms to FGFR inhibitors in FG⁃
［58］ZHENG L L，CAO J Q，MA L，et al. LC⁃MF⁃4，a novel FG⁃ FR2 ⁃ altered cholangiocarcinoma［J］. Clin Cancer Res，
FR3 degrader for therapeutic intervention in FGFR3⁃al⁃ 2024，30（1）：198-208
tered cancers［J］. J Med Chem，2025，68（13）：13858- ［70］GANDHY S U，CASAK S J，MUSHTI S L，et al. FDA ap⁃
13871 proval summary：futibatinib for unresectable advanced or
［59］LEE H，RYU M H，LEE I S，et al. Low positivity rate of fi⁃ metastatic，chemotherapy refractory intrahepatic cholangio⁃
broblast growth factor receptor 2b is associated with het⁃ carcinoma with FGFR2 fusions or other rearrangements［J］.
erogeneous expression in gastric cancer［J］. Gastric Can⁃ Clin Cancer Res，2023，29（20）：4027-4031
cer，2025，28（4）：598-608 ［71］NOERAPARAST M，KRAJINA K，PICHLER R，et al. FG⁃
［60］CHATURANTABUT S，OLIVER S，FREDERICK D T，et FR3 alterations in bladder cancer：sensitivity and resis⁃
al. Identification of potent biparatopic antibodies target⁃ tance to targeted therapies［J］. Cancer Commun（Lond），
ing FGFR2 fusion⁃driven cholangiocarcinoma［J］. J Clin 2024，44（10）：1189-1208
Investig，2025，135（8）：e182417 ［72］DIPERI T P，ZHAO M，EVANS K W，et al. Convergent
［61］YANG Y，SUHASINI A N，JIANG Z L，et al. A tetra⁃ MAPK pathway alterations mediate acquired resistance to
valent bispecific antibody selectively inhibits diverse FGFR inhibitors in FGFR2 fusion⁃positive cholangio⁃
FGFR3 oncogenic variants［J］. Cancer Res，2024，84 carcinoma［J］. J Hepatol，2024，80（2）：322-334
（13）：2169-2180 ［73］MAKABE S，HOSHI K，KANEKO H，et al. MET signal⁃
［62］KRZYSCIK M A，POREBSKA N，OPALINSKI Ł，et al. ing drives acquired resistance to erdafitinib in muscle⁃in⁃
Targeting HER2 and FGFR⁃positive cancer cells with a vasive bladder cancer cells［J］. Cell Death Dis，2025，16
bispecific cytotoxic conjugate combining anti⁃HER2 Affi⁃ （1）：868
body and FGF2［J］. Int J Biol Macromol，2024，254（Pt （下转第1436页）